This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Paul H. Lange, MD

JAMA. 1995;273(4):336-337.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The tumor marker prostate-specific antigen (PSA) has changed the way we think about and manage carcinoma of the prostate to a degree unprecedented in human oncology. Elevated serum concentrations can occur in men with benign prostatic hyperplasia but are more frequent and higher in those with cancer. Serum PSA measurements have become indispensable for monitoring disease, but their use for screening is controversial and highlights the paradoxes of this neoplasm.

See also p 289.

What confuses us about prostate cancer is that it usually grows slowly and is predominately a malady of aging. Among men older than 70 years who die of something else, 30% also have "autopsy" cancer of the prostate, usually with cancer volumes less than 0.2 cm³ and low-grade cell types.¹ Yet prostate cancer is the second leading cause of male cancer death. Clinical cancer of the prostate can only be cured if localized, and . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Urology, University of Washington School of Medicine, Seattle.

Footnotes
Reprint requests to Department of Urology, University of Washington School of Medicine, RL-10, Seattle, WA 98195 (Dr Lange).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?